 |
 |
 |
August, 2010
25th Annual Report 2009-10 |
| |
|
|
May 31, 2010
Audited Financial Result For March 2010 Qtr |
| |
|
|
January 27, 2010
Unaudited Financial Result For December 2009 Qtr |
| |
 |
|
| |
 |
 |
 |
|
| Click here to know more about your health and health care info... |
|
|
|
 |
|
 |
|
| |
|
| |
 |
 |
 |
| |
| LOFNAC - 50 / 100 Delayed Release Tablets |
| Composition |
DICLOFENAC
SODIUM USP 100 mg
DICLOFENAC SODIUM USP 50 mg |
| Pharmacokinetics |
After oral
administration, Diclolenac Is rapidly and completely
absorbed The plasma concentrations are
linearly dose dependant. |
| Indications |
Rheumatoid arthritis. Ankylosing
spondylitis, Acute painful shoulder.
Postoperative pain,
Musculoskeletal injuries, Dysmenorrhoea,
Sprain, Dislocation, Tenosynovitis,
Tendinitis. |
| Properties and Action |
The active agent
Diclofenac belongs to the non-steroid anti-
inflammatory group and
exhibits marked anli-rheumatic. anti-
inflammatory and
analgesic properties. Diclofenac inhibits
prostaglandin
synthetase and has an inhibitory action on platelet
aggregation Lofnac is
thus suitable for the treatment of rheumatic
stales and
non-rheumatic pain, inflammatory pain.
Lofnac tablets have
protective coating to gastric juices Lofnac tablets
are suitable for
patients whose clinical condition indicates a daily dose
of 100 mg |
|
|
| |
|
|
Back 